

January 31, 2014

Fonditaria – SAI SPA – Name and Ratio Change

Please be advised that Fonditaria – SAI SPA announced a name change to UnipolSai Assicurazioni S.p.A. BNY Mellon as Depositary will change the ratio of the Depositary Receipt (“DR”) program from 10 DRs representing 1 Common share to 1 DR representing 4 Common shares, effective February 10, 2014.

The following identifiers have been assigned.

| | | | |
|---------------|-------------------------|---------------|------------------------|
| Old CUSIP: | 344588108 | New CUSIP: | 90916Q106 |
| Old DR ISIN: | US3445881085 | New DR ISIN: | US90916Q1067 |
| Old DR Ratio: | 10 DRs : 1 Common Share | New DR Ratio: | 1 DR : 4 Common Shares |

The effective date for the changes will be February 10, 2014.

Since there are no DRs outstanding, no exchange of DR certificates is required. DR holders need not take any action. Existing DR certificates will assume the new parameters and will not be subject to a mandatory exchange.

The Books were closed as of the close of business January 30, 2014 and will reopen on February 10, 2014 for Issuance transactions.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Melissa Sobolewski/Ravi Davis
+1 212 815-2267
Adrdesk@bnymellon.com

London

Damon Rowan
Vice President
+44 207 964 6527
damon.rowan@bnymellon.com

Hong Kong

Herston Powers
Vice President
+852 2 840 9868
herston.powers@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers. This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.